ஆஂக் சிகிச்சை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation.
Immune-Onc Therapeutics Announces First Public Presentation of Data for its Myeloid Checkpoint Inhibitor, IO-202, in Solid Tumors at AACR21
April 10, 2021 GMT
PALO ALTO, Calif. (BUSINESS WIRE) Apr 10, 2021
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced today the first public presentation of preclinical data for its first-in-class myeloid checkpoint inhibitor, IO-202, an LILRB4 antagonist antibody, in solid tumors. The electronic poster will be presented as part of the Immune Checkpoints Session of the American Association for Cancer Research (AACR) Annual Meeting 2021 (#AACR21), taking place virtually April 10-15, 2021. ....

Palo Alto , United States , Tara Cooper , Albert Einstein College Of Medicine , Grace Communication Group , Onc Therapeutics Inc , Drug Administration , University Of Texas , Memorial Sloan Kettering Cancer Center , Onc Therapeutics , Immune Checkpoints Session , American Association , Cancer Research , Annual Meeting , Poster Presentation Details , Drug Designation , Leukocyte Immunoglobulin Like Receptor , Albert Einstein College , Immune Onc Therapeutics , Business Wire , பாலோ ஆல்டோ , ஒன்றுபட்டது மாநிலங்களில் , தாரா கூப்பர் , ஆல்பர்ட் ஐன்ஸ்டீன் கல்லூரி ஆஃப் மருந்து , கருணை தொடர்பு குழு , ஆஂக் சிகிச்சை இன்க் ,